This was the 10th year of the World Vaccine Congress. This event attracts a wide range of participants not only from traditional areas, such as biopharma, academia and government organizations, but also from associated fields, such as venture capital firms, law firms and consultants. The 2008 event began with a rocky start in the midst of the global financial meltdown. A premeeting day set aside to focus on investment opportunities and the financial aspects of vaccine development was thrown into turmoil as speakers from various investment houses had to withdraw as their various sponsors faced uncertain economic times. The next 3 days of the meeting contained the bulk of the scientific portions. As the number of oral presentations were too numerous to all be covered in this review, selected highlights will be discussed.